Compile Data Set for Download or QSAR
Report error Found 1229 with Last Name = 'young' and Initial = 'jm'
TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289769(US10093673, Compound 1.1)
Affinity DataEC50:  0.100nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM246811(cis-10-methoxy-11-(3-methoxypropoxy)-3,3-dimethyl-...)
Affinity DataEC50:  13nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM246810(trans-10-methoxy-11-(3-methoxypropoxy)-3,3-dimethy...)
Affinity DataEC50:  460nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289772(US10093673, Compound 3.1)
Affinity DataEC50:  0.300nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289773(US10093673, Compound 3.2)
Affinity DataEC50:  740nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289774(US10093673, Compound 4.1)
Affinity DataEC50:  0.300nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289775(US10093673, Compound 5.1)
Affinity DataEC50:  6nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289776(US10093673, Compound 5.2)
Affinity DataEC50:  0.100nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289777(US10093673, Compound 6.1 | US10093673, Compound 6....)
Affinity DataEC50:  9nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289777(US10093673, Compound 6.1 | US10093673, Compound 6....)
Affinity DataEC50:  5nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289779(US10093673, Compound 7.1)
Affinity DataEC50:  0.800nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289780(US10093673, Compound 7.2)
Affinity DataEC50:  90nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289781(US10093673, Compound 8.1)
Affinity DataEC50:  1nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289782(US10093673, Compound 9.1 | US10093673, Compound 9....)
Affinity DataEC50:  9nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Novartis

US Patent
LigandPNGBDBM289782(US10093673, Compound 9.1 | US10093673, Compound 9....)
Affinity DataEC50:  303nMAssay Description:HepG2-Clone42 cells were seeded in into black clear-bottom 96-well plates at a concentration of 6.0×104 cells/well. 24 hours post-seeding, the cells ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2019
Entry Details
Go to US Patent

LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 0.488nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 0.488nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 0.488nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 0.669nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 0.669nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 0.669nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285537(US10077269, Example 10 | 3-(4-chloro-3-fluoro-phen...)
Affinity DataIC50: 1.51nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285537(US10077269, Example 10 | 3-(4-chloro-3-fluoro-phen...)
Affinity DataIC50: 1.51nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285537(US10077269, Example 10 | 3-(4-chloro-3-fluoro-phen...)
Affinity DataIC50: 1.51nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 1.59nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 1.59nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 1.59nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285538(US10077269, Example 11 | N-cyclopropyl-3-(3,4-di-c...)
Affinity DataIC50: 1.60nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285538(US10077269, Example 11 | N-cyclopropyl-3-(3,4-di-c...)
Affinity DataIC50: 1.60nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285538(US10077269, Example 11 | N-cyclopropyl-3-(3,4-di-c...)
Affinity DataIC50: 1.60nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 1.89nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 1.89nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 1.89nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285572(US10077269, Example 45 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 1.97nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285572(US10077269, Example 45 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 1.97nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285572(US10077269, Example 45 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 1.97nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 2nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.35nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.35nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.35nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.77nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.77nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.77nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 2.82nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 2.82nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 2.82nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM285572(US10077269, Example 45 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 2.91nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285572(US10077269, Example 45 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 2.91nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1229 total ) | Next | Last >>
Jump to: